Results showed that Hemlibra’s safety profile was consistent with previous observations and no new safety signals were observed after the longer follow-up... Dec 07
CPI-818, an oral interleukin-2-inducible T-cell kinase inhibitor, is well-tolerated and active in patients with T-cell lymphoma... Dec 07
-Advertisements-